AC

AC Immune is a clinical-stage Swiss biopharmaceutical company specializing in precision medicine for neurodegenerative diseases. The company leverages its proprietary SupraAntigen and Morphomer technology platforms to develop a diverse pipeline of therapeutic and diagnostic candidates targeting misfolded proteins. Its portfolio includes active immunotherapies (vaccines), monoclonal antibodies, and small molecules focused on Alzheimer's disease, Parkinson's disease, and other proteinopathies. AC Immune has established significant strategic partnerships with global pharmaceutical leaders, including Takeda, Eli Lilly, and Johnson & Johnson, to advance its most promising candidates through clinical development.